There is a newer version of this record available.

Working paper Open Access

Ivermectin for Covid-19

Sparavigna, Amelia Carolina

Discussion of scholar papers published until  10 July, 2020,  on Ivermectin, and of some news that we can find about its use for Covid-19.  A list of clinical trials is also given. For what concerns scholar papers, we report among them a preprint posted on 10 June in MedRχiv,  which concludes that Ivermectin was associated with lower mortality during treatment of Covid-19.  We report also the preprint, posted on 8 July in MedRχiv too, showing the result of a clinical trial. The preprint tells, in its conclusions that add-on use of Ivermectin is giving better results when compared to controls, in particular a significant shorter hospital stay. From news, we consider in particular the case of Iquitos,  capital city of the Loreto Region in Peru, where, by May 25, Covid-19 cases and deaths had dropped notably, as reported on the web. The formulation of ivermectin used in Peru is also discussed, in particular that of the oral solution disclosed by the Peruvian Government. 

Before reading this work, please consider that I am not a physician. I do not suggest the use of ivermectin. I am not touting this drug. This analysis of publications and news about ivermectin is made in the framework of a wider investigation about information concerning drugs used for Covid-19.
Files (315.2 kB)
Name Size
Ivermectin-13.pdf
md5:c7c908788a24972f33041b161c2d23da
315.2 kB Download
3,957
1,371
views
downloads
All versions This version
Views 3,957322
Downloads 1,37190
Data volume 355.3 MB28.4 MB
Unique views 3,242291
Unique downloads 1,14180

Share

Cite as